New combo aims to shrink esophageal tumors before surgery
NCT ID NCT06952621
First seen Feb 02, 2026 · Last updated May 12, 2026 · Updated 8 times
Summary
This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with resectable locally advanced esophageal squamous cell carcinoma. About 390 adults aged 18-75 will be randomly assigned to receive either toripalimab plus nab-paclitaxel and platinum, or a standard chemo regimen (DCF). The main goal is to see if the new combination leads to a higher rate of complete tumor disappearance (pathological complete response) after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospitial, Xi'an, Shaanxi Rrovince
Xi'an, Shaanxi, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.